Fresh Tracks Therapeutics, Inc. Common Stock
FRTX
FRTX was delisted on the 18th of December, 2023.
17 hedge funds and large institutions have $2.71M invested in Fresh Tracks Therapeutics, Inc. Common Stock in 2019 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 5 reducing their positions, and 9 closing their positions.
20.77% less ownership
Funds ownership: 29.09% → 8.32% (-21%)
23% less funds holding
Funds holding: 22 → 17 (-5)
40% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 5
52% less capital invested
Capital invested by funds: $5.64M → $2.71M (-$2.94M)
56% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$217K |
| 2 |
NFG
Next Financial Group
Houston,
Texas
|
+$29.6K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$5.74K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$4.13K |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
+$2.53K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Sio Capital Management
New York
|
-$1.13M |
| 2 |
FI
Fosun International
Hong Kong,
China
|
-$265K |
| 3 |
BI
BVF Inc
San Francisco,
California
|
-$169K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$139K |
| 5 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$114K |
FRTX Hedge Fund Activity: Q3 2019 in Review
17 of the 4,574 institutional investors tracked by Wall St. Rank reported a position in Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) for Q3 2019, worth a combined $2.71M — down 52% from $5.64M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of FRTX and 4 opened new positions — a net loss of 5 holders — while 5 trimmed existing stakes and 3 added.
The largest buyer was Renaissance Technologies, adding an estimated $217K. The largest seller was Sio Capital Management, exiting entirely with an estimated $1.13M sold.
- 17 institutional investors held Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) as of Q3 2019, down from 22 in Q2 2019.
- Funds reported $2.71M of Fresh Tracks Therapeutics, Inc. Common Stock stock for Q3 2019, down 52% quarter-over-quarter.
- 4 funds opened new Fresh Tracks Therapeutics, Inc. Common Stock positions in Q3 2019 and 9 closed out, a net change of -5 holders.
- The largest Fresh Tracks Therapeutics, Inc. Common Stock buyer in Q3 2019 was Renaissance Technologies, an estimated $217K added.
- The largest Fresh Tracks Therapeutics, Inc. Common Stock seller in Q3 2019 was Sio Capital Management, an estimated $1.13M sold.
Based on aggregated 13F filings for Q3 2019.